Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.59 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.50 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1757239 | 0.92 | HTT (0.63) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL652527 | 0.85 | LMNA (0.60) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL7378562 | 0.85 | LMNA (0.65) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL16533444 | 0.84 | LMNA (0.60) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL26630558 | 0.84 | LMNA (0.63) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL966270 | 0.84 | LMNA (0.63) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL7752769 | 0.83 | LMNA (0.67) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL16384886 | 0.83 | HTT (0.53) | LMNASMN1; SMN2HTTTGM2KEAP1 | |
| SCHEMBL10349459 | 0.83 | LMNA (0.58) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL10243339 | 0.83 | LMNA (0.71) | LMNASMN1; SMN2SLC1A3SLC1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250136550-A1 | PROCESSES FOR PREPARING REVEFENACIN AND COMPOSITIONS COMPRISING THE SAME | THERAVANCE BIOPHARMA R&D IP, LLC | 2025-05-01 | — | — | US | disclosed |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | YALE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| CN-113164775-A | Polycyclic compounds and methods for rapid accelerated targeted degradation of fibrosarcoma polypeptides | 阿尔维纳斯运营股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3846907-A1 | POLYCYCLIC COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | Arvinas Operations, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2020-04-30 | — | — | US | disclosed |
| EP-2593429-B1 | PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-06-03 | — | — | EP | disclosed |
| US-9035061-B2 | Process for preparing a biphenyl-2-ylcarbamic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-05-19 | — | — | US | disclosed |
| US-8754225-B2 | Process for preparing a biphenyl-2-ylcarbamic acid | THERAVANCE, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20140121378-A1 | PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID | THERAVANCE, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| EP-2593429-A1 | PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID | Theravance, Inc. (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20120016130-A1 | PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC | 2012-01-19 | — | — | US | disclosed |
| WO-2012009166-A1 | PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID | THERAVANCE, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136550-A1 | PROCESSES FOR PREPARING REVEFENACIN AND COMPOSITIONS COMPRISING THE SAME | CYP4B1, KDM4B, CYP3A4 | LMNA 933/4885SMN1; SMN2 1845/4885SLC1A3 4650/4885 |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | LMNA 1887/4885SMN1; SMN2 2113/4885SLC1A3 4295/4885 |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | CRBN, ARAF, VHL | LMNA 1887/4885SMN1; SMN2 2113/4885SLC1A3 4295/4885 |
| US-20140121378-A1 | PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID | CYP4B1, KDM2B, CYP26B1 | LMNA 326/4885SMN1; SMN2 4248/4885SLC1A3 3623/4885 |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | LMNA 1887/4885SMN1; SMN2 2113/4885SLC1A3 4295/4885 |
| US-20120016130-A1 | PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID | CYP4B1, KDM2B, CYP26B1 | LMNA 326/4885SMN1; SMN2 4248/4885SLC1A3 3623/4885 |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | LMNA 1887/4885SMN1; SMN2 2113/4885SLC1A3 4295/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | LMNA 1254/4885SMN1; SMN2 2142/4885SLC1A3 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.